Edition:
United States

XBiotech Inc (XBIT.OQ)

XBIT.OQ on NASDAQ Stock Exchange Global Select Market

4.27USD
18 May 2018
Change (% chg)

$-0.02 (-0.47%)
Prev Close
$4.29
Open
$4.32
Day's High
$4.32
Day's Low
$4.22
Volume
25,230
Avg. Vol
23,830
52-wk High
$11.85
52-wk Low
$2.80

Chart for

About

XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response. The Company has also... (more)
No analyst recommendations are available for .

Overall

Beta: --
Market Cap(Mil.): $157.97
Shares Outstanding(Mil.): 35.42
Dividend: --
Yield (%): --

Financials

  XBIT.OQ Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -1.47 -- --
ROI: -62.28 1.57 14.38
ROE: -62.30 2.43 16.07

BRIEF-XBiotech Announces First Patient In Phase 2 Study Evaluating Patients With Atopic Dermatitis

* XBIOTECH ANNOUNCES FIRST PATIENT IN PHASE 2 STUDY EVALUATING MABP1 IN PATIENTS WITH ATOPIC DERMATITIS Source text for Eikon: Further company coverage:

May 22 2018

BRIEF-XBiotech Announces Upcoming Phase 2 Clinical Studies In Dermatology

* XBIOTECH ANNOUNCES UPCOMING PHASE 2 CLINICAL STUDIES IN DERMATOLOGY

Apr 16 2018

BRIEF-Xbiotech Announces Upcoming Phase 2 Clinical Studies In Dermatology

* XBIOTECH ANNOUNCES UPCOMING PHASE 2 CLINICAL STUDIES IN DERMATOLOGY

Apr 16 2018

BRIEF-XBiotech In-Licenses Anti-NY-ESO 1 Antibody Targeting Advanced Cancer

* HAS OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG Source text for Eikon: Further company coverage:

Apr 02 2018

Earnings vs. Estimates